What is Correlia Biosystems?
Correlia Biosystems operates at the intersection of biotechnology and advanced engineering, specializing in microscale analysis for protein measurement. The company's flagship PIXI platform represents a next-generation automated immunoassay system that addresses critical bottlenecks in biopharmaceutical analysis, cell and gene therapy, and synthetic biology. By enabling highly accurate and reproducible protein quantification with minimal sample input, Correlia provides researchers with the tools necessary for rapid turnaround times in complex experimental workflows. Their business model, which includes both off-the-shelf and custom assay solutions, is built upon deep collaborations with leading pharmaceutical entities, ensuring that their technological advancements remain aligned with the rigorous demands of modern drug discovery and clinical development.
How much funding has Correlia Biosystems raised?
Correlia Biosystems has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2020): $7M with participation from Cota Capital and Neotribe Ventures
Key Investors in Correlia Biosystems
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector, combining financial investment with deep operational expertise.
Neotribe Ventures
Neotribe Ventures is a Silicon Valley-based venture capital firm that identifies and funds entrepreneurs developing breakthrough technologies with the potential to create transformative market movements.
What's next for Correlia Biosystems?
With this major strategic investment, Correlia Biosystems is poised to scale its operational capacity and expand its market footprint within the global life sciences sector. The company is expected to leverage this capital to enhance its R&D initiatives, focusing on the next iteration of the PIXI platform to further improve sensitivity and throughput. As the demand for high-fidelity proteomics data continues to rise in the biopharmaceutical industry, Correlia's ability to provide scalable, automated solutions will be a key driver of its long-term growth. Future strategic milestones will likely include the expansion of their custom assay service offerings and the strengthening of their commercial partnerships to penetrate deeper into the synthetic biology and therapeutic development markets.
See full Correlia Biosystems company page
